-
公开(公告)号：US12202879B2
公开(公告)日：2025-01-21
申请号：US17255629
申请日：2019-06-27
Inventor： Sang Taek Jung , Ji Yeon Ha
IPC: C07K14/705 , C12N15/10 , A61K38/00
Abstract: A PD-L1 mutant having improved binding affinity for PD-1 is disclosed. A method for preparing the PD-L1 variant and a method for screening the PD-L1 variant are also disclosed. The PD-L1 variant produced by substituting some amino acids in the sequence of wild-type PD-L1 with other optimal amino acids, achieving greatly improved affinity for PD-1. In addition, the possibility of immunogenicity can be reduced by the smallest possible number of the mutation sites.
-
公开(公告)号：US11650209B2
公开(公告)日：2023-05-16
申请号：US16628427
申请日：2018-09-13
Inventor： Sang Taek Jung , Migyeong Jo , Sanghwan Ko , Bora Hwang
CPC classification number: G01N33/6857 , C07K14/70535 , A61K38/00 , C07K16/46 , C07K2319/31 , C12N5/00 , C12N15/00 , G01N33/53
Abstract: The present disclosure relates to a polypeptide including an Fc-gamma receptor mutant. The Fc-gamma receptor mutant of the present disclosure is optimized by substituting a part of an amino acid sequence of an Fc-gamma receptor with a different amino acid sequence, so as to provide an excellent selective binding ability to immunoglobulins. Therefore, it can be usefully used for increasing in vivo half-life of drugs, detecting and purifying immunoglobulins, inhibiting organ transplant rejections, or preventing or treating autoimmune diseases.
-
公开(公告)号：US11492415B2
公开(公告)日：2022-11-08
申请号：US16603273
申请日：2018-04-06
Applicant: KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION , OSONG MEDICAL INNOVATION FOUNDATION
Inventor： Sang Taek Jung , Sanghwan Ko , Tae Gyu Lee , So Young Choi , Soo Han Lee , Myung Ho Sohn , Su Jin Kim , So Ra Park , Jong Shik Park , Ju Hyeon Lim
Abstract: The present invention relates to a polypeptide including an Fc variant produced by substituting a portion of the amino acid sequence of the Fc domain of a human antibody with a different amino acid sequence. The present invention also relates to an antibody including the polypeptide. The Fc variant can find application in a wide range of antibodies and Fc-fusion constructs. In one aspect, the antibody or Fc fusion construct of the present invention is a therapeutic, diagnostic or laboratory reagent, preferably a therapeutic reagent. The Fc variant is suitable for use in the treatment of cancer because its in vivo half-life can be maximized by optimization of the portion of the amino acid sequence. The antibody or Fc fusion construct of the present invention is used to kill target cells that bear a target antigen, for example cancer cells. Alternatively, the antibody or Fc fusion construct of the present invention is used to block, antagonize or agonize a target antigen. For example, the antibody or Fc fusion construct of the present invention may be used to antagonize a cytokine or a cytokine receptor.
-
公开(公告)号：US11414493B2
公开(公告)日：2022-08-16
申请号：US16345062
申请日：2017-08-22
Inventor： Sang Taek Jung , Migyeong Jo
IPC: C07K1/00 , A61K39/00 , C07K16/28 , A61P35/00 , A61K39/395
Abstract: The present disclosure relates to a polypeptide containing an Fc domain in which a part of an amino acid sequence of a human antibody Fc domain is substituted with another amino acid sequence, or an aglycosylated antibody containing the same. The Fc domain of the present disclosure is optimized by substituting a part of an amino acid sequence of a wild-type Fc domain with another amino acid sequence. Therefore, it is useful in treatment of cancer due to superior selective binding ability to FcγRIIIa among Fc receptors, and can be prepared as a homogeneous aglycosylated antibody through bacterial culture.
-
-
-
Search Results
4
records
(took 0.017 seconds)
